Cocrystal Pharma Inc. to Present at Noble Capital Markets’ 16th Annual Investor Conference
February 11, 2020 08:35 ET
|
Cocrystal Pharma, Inc.
– Presentation on Tuesday, February 18th at 11:30 AM ET – BOTHELL, WA, Feb. 11, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage...
COCRYSTAL PHARMA, INC. ANNOUNCES CLOSING OF $2.2 MILLION REGISTERED DIRECT OFFERING
February 03, 2020 08:05 ET
|
Cocrystal Pharma, Inc.
BOTHELL, WA, Feb. 03, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral...
COCRYSTAL PHARMA, INC. PRICES $2.2 MILLION REGISTERED DIRECT OFFERING
January 29, 2020 09:45 ET
|
Cocrystal Pharma, Inc.
BOTHELL, WA, Jan. 29, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral...
COCRYSTAL PHARMA, INC. ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK
October 30, 2019 16:45 ET
|
Cocrystal Pharma, Inc.
BOTHELL, WA, Oct. 30, 2019 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral...
Cocrystal Pharma Announces New Data on CC-31244 and Abstract Acceptance for Poster Presentation at the AASLD 2019 Liver Meeting
October 30, 2019 08:05 ET
|
Cocrystal Pharma, Inc.
New data to be presented from U.S. Phase 2a clinical trial of CC-31244 for ultrashort treatment of hepatitis C virus (HCV)Eight of 12 patients achieved primary endpoint of sustained virologic response...
Cocrystal Pharma Presents Positive Preclinical Data for CC-42344 at the Options X for the Control of Influenza Conference
September 03, 2019 08:05 ET
|
Cocrystal Pharma, Inc.
- CC-42344 showed broad spectrum activity, excellent anti-influenza activity (EC50 <1 nM), and a strong synergistic effect with approved influenza antivirals - - Preclinical study...
Cocrystal Pharma Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 10, 2019 08:35 ET
|
Cocrystal Pharma, Inc.
– Company is well positioned to achieve multiple corporate, clinical and research value-driving milestones in 2019 – BOTHELL, WA, May 10,...
Cocrystal Pharma Reports 2018 Financial Results and Provides Corporate Overview and Business Outlook
April 01, 2019 08:35 ET
|
Cocrystal Pharma, Inc.
– Exclusive worldwide license and collaboration agreement with Merck further validates Company’s approach to creating first- and best-in-class antiviral drugs and expected to enable rapid advancement...
Cocrystal Pharma Announces Closing of Private Placement
March 11, 2019 08:30 ET
|
Cocrystal Pharma, Inc.
BOTHELL, WA, March 11, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel...
Cocrystal Announces Board Changes
January 07, 2019 08:30 ET
|
Cocrystal Pharma, Inc.
BOTHELL, WA, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc., a biotechnology company with a proprietary technology platform focused on developing medicines to treat viral diseases, today...